Network meta-analysis

Discontinuation due to gastrointestinal adverse events

Type 2 diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)

Randomized trials

Treatments

19,824

Participants

650

Events

In plain language

Across 41 trials with 19,824 participants, 3 of 45 treatments had a clearly better result than placebo on discontinuation due to gastrointestinal adverse events, 9 a clearly worse one, and for 33 the evidence could not tell them apart from placebo. The most favorable estimate was for Insulin glargine: hazard ratio (from event counts) 0.02 (95% credible interval 0.00 to 0.19).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Insulin glargine INS_GLARGINE	0.02 (0.00 to 0.19)	0.00 to 0.21	Better
Insulin aspart (prandial) INS_ASPART	0.07 (0.00 to 0.80)	0.00 to 0.84	Better
Sulfonylurea OTHER_ACTIVE_sulfonylurea	0.09 (0.00 to 1.05)	0.00 to 1.16	Unclear
Dapagliflozin DAPAGLIFLOZIN	0.09 (0.00 to 1.77)	0.00 to 1.85	Unclear
Additional oad OTHER_ACTIVE_additional_OAD	0.11 (0.00 to 1.31)	0.00 to 1.37	Unclear
Investigator choice oral drug OTHER_ACTIVE_investigator_choice_oral_drug	0.21 (0.01 to 4.79)	0.01 to 5.04	Unclear
Sitagliptin SITAGLIPTIN	0.21 (0.06 to 0.64)	0.05 to 0.72	Better
Dulaglutide 0.75 mg subcutaneous once weekly DULA_SC_0p75MG_QW	0.42 (0.06 to 2.26)	0.06 to 2.47	Unclear
Standard care or no added treatment STANDARD_CARE	0.58 (0.01 to 31.91)	0.01 to 32.82	Unclear
Dulaglutide 0.25 mg injection once weekly DULA_SC_0p25MG_QW	0.63 (0.01 to 47.95)	0.01 to 47.34	Unclear
Dulaglutide 0.5 mg injection once weekly DULA_SC_0p5MG_QW	0.63 (0.01 to 49.51)	0.01 to 50.31	Unclear
IGlarLixi 2:1 pen subcutaneous once daily titrated IGLARLIXI2_SC_TIT_QD	0.70 (0.03 to 23.59)	0.03 to 24.18	Unclear
Metformin METFORMIN	0.71 (0.01 to 47.85)	0.01 to 53.09	Unclear
Liraglutide and metformin 1.2 to 1500 mg injection once daily LIRAMETF_SC_1p2-1500MG_QD	0.74 (0.01 to 52.55)	0.01 to 53.39	Unclear
Semaglutide 3 mg oral once daily (original tablet) SEMA_PO_3MG_QD	1.26 (0.17 to 7.04)	0.15 to 7.52	Unclear
Liraglutide flexible dose injection once daily LIRA_SC_FLEX_0p6-1p2-1p8_QD	1.30 (0.05 to 26.89)	0.05 to 30.12	Unclear
Tirzepatide 5 mg subcutaneous once weekly TIRZ_SC_5MG_QW	1.43 (0.16 to 9.76)	0.15 to 10.29	Unclear
Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW	1.47 (0.08 to 31.64)	0.07 to 33.35	Unclear
Danuglipron 120 mg oral twice daily DANU_PO_120MG_BID	1.49 (0.08 to 21.90)	0.08 to 22.59	Unclear
Efpeglenatide 2 mg subcutaneous once weekly EFPE_SC_2MG_QW	1.53 (0.32 to 7.36)	0.29 to 7.99	Unclear
Dulaglutide 1.5 mg subcutaneous once weekly DULA_SC_1p5MG_QW	1.53 (0.19 to 10.98)	0.17 to 11.73	Unclear
Exenatide extended release 2 mg subcutaneous once weekly EXENER_SC_2MG_QW	1.76 (0.68 to 4.49)	0.58 to 5.23	Unclear
Liraglutide 0.9 mg injection once daily LIRA_SC_0p9MG_QD	2.16 (0.21 to 23.65)	0.19 to 25.05	Unclear
Semaglutide 2.4 mg subcutaneous once weekly SEMA_SC_2p4MG_QW	2.19 (0.86 to 5.92)	0.72 to 6.79	Unclear
Safiglipron (HRS-7535) 30 mg tablet once daily SAFIGL_PO_30MG_QD	2.32 (0.33 to 20.50)	0.30 to 23.04	Unclear
Taspoglutide 10 mg subcutaneous once weekly TASP_SC_10MG_QW	2.45 (0.49 to 12.29)	0.45 to 13.00	Unclear
Tirzepatide 12 mg injection once weekly TIRZ_SC_12MG_QW	2.51 (0.11 to 53.88)	0.11 to 59.59	Unclear
Taspoglutide 20 mg subcutaneous once weekly TASP_SC_20MG_QW	2.70 (0.55 to 13.54)	0.51 to 14.44	Unclear
Semaglutide 0.5 mg subcutaneous once weekly SEMA_SC_0p5MG_QW	2.71 (1.19 to 6.38)	0.98 to 7.47	Worse
Semaglutide 7 mg oral once daily (original tablet) SEMA_PO_7MG_QD	2.74 (0.50 to 12.91)	0.45 to 13.95	Unclear
Efpeglenatide 4 mg subcutaneous once weekly EFPE_SC_4MG_QW	2.74 (0.69 to 12.10)	0.63 to 13.33	Unclear
Danuglipron 40 mg oral twice daily DANU_PO_40MG_BID	3.27 (0.32 to 37.72)	0.30 to 40.99	Unclear
Semaglutide 2.0 mg subcutaneous once weekly SEMA_SC_2p0MG_QW	3.35 (0.58 to 24.16)	0.52 to 25.57	Unclear
Safiglipron (HRS-7535) 60 mg tablet once daily SAFIGL_PO_60MG_QD	3.72 (0.57 to 32.76)	0.53 to 34.85	Unclear
Safiglipron (HRS-7535) 90 mg tablet once daily SAFIGL_PO_90MG_QD	4.11 (0.68 to 37.29)	0.64 to 41.60	Unclear
Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW	4.37 (2.08 to 9.87)	1.76 to 11.65	Worse
Liraglutide 1.8 mg subcutaneous once daily LIRA_SC_1p8MG_QD	4.48 (2.03 to 10.97)	1.73 to 13.07	Worse
Semaglutide 14 mg oral once daily (original tablet) SEMA_PO_14MG_QD	4.59 (1.67 to 12.22)	1.45 to 13.64	Worse
Insulin icodec and semaglutide (IcoSema) subcutaneous once weekly titrated ICOSEMA_SC_TIT_QW	4.76 (0.71 to 32.30)	0.65 to 33.82	Unclear
Efpeglenatide 6 mg subcutaneous once weekly EFPE_SC_6MG_QW	5.31 (1.56 to 21.98)	1.36 to 24.70	Worse
Semaglutide 16 mg injection once weekly SEMA_SC_16MG_QW	5.65 (1.05 to 39.00)	0.96 to 41.44	Worse
Danuglipron 80 mg oral twice daily DANU_PO_80MG_BID	6.50 (0.69 to 70.61)	0.66 to 76.12	Unclear
Lixisenatide 20 ug subcutaneous once daily LIXI_SC_20UG_QD	6.61 (1.62 to 39.34)	1.48 to 42.74	Worse
Exenatide 10 ug subcutaneous twice daily EXEN_SC_10UG_BID	7.47 (1.45 to 49.00)	1.36 to 52.45	Worse
Semaglutide 8 mg injection once weekly SEMA_SC_8MG_QW	11.13 (2.33 to 73.87)	2.08 to 79.14	Worse

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	INS_GLARGINE	INS_ASPART	OTHER_ACTIVE_sulfonylurea	DAPAGLIFLOZIN	OTHER_ACTIVE_additional_OAD	OTHER_ACTIVE_investigator_choice_oral_drug	SITAGLIPTIN	DULA_SC_0p75MG_QW	STANDARD_CARE	DULA_SC_0p25MG_QW	DULA_SC_0p5MG_QW	IGLARLIXI2_SC_TIT_QD	METFORMIN	LIRAMETF_SC_1p2-1500MG_QD	SEMA_PO_3MG_QD	LIRA_SC_FLEX_0p6-1p2-1p8_QD	TIRZ_SC_5MG_QW	TIRZ_SC_15MG_QW	DANU_PO_120MG_BID	EFPE_SC_2MG_QW	DULA_SC_1p5MG_QW	EXENER_SC_2MG_QW	LIRA_SC_0p9MG_QD	SEMA_SC_2p4MG_QW	SAFIGL_PO_30MG_QD	TASP_SC_10MG_QW	TIRZ_SC_12MG_QW	TASP_SC_20MG_QW	SEMA_SC_0p5MG_QW	SEMA_PO_7MG_QD	EFPE_SC_4MG_QW	DANU_PO_40MG_BID	SEMA_SC_2p0MG_QW	SAFIGL_PO_60MG_QD	SAFIGL_PO_90MG_QD	SEMA_SC_1p0MG_QW	LIRA_SC_1p8MG_QD	SEMA_PO_14MG_QD	ICOSEMA_SC_TIT_QW	EFPE_SC_6MG_QW	SEMA_SC_16MG_QW	DANU_PO_80MG_BID	LIXI_SC_20UG_QD	EXEN_SC_10UG_BID	SEMA_SC_8MG_QW
PLACEBO	PLACEBO	60.42 5.19 to 1726	13.87 1.25 to 524	11.51 0.95 to 449	10.74 0.57 to 468	9.48 0.76 to 396	4.75 0.21 to 123	4.72 1.57 to 17.07	2.40 0.44 to 15.99	1.71 0.03 to 159	1.59 0.02 to 168	1.58 0.02 to 185	1.43 0.04 to 34.57	1.41 0.02 to 145	1.34 0.02 to 154	0.79 0.14 to 6.05	0.77 0.04 to 19.98	0.70 0.10 to 6.34	0.68 0.03 to 13.11	0.67 0.05 to 11.88	0.66 0.14 to 3.11	0.65 0.09 to 5.24	0.57 0.22 to 1.47	0.46 0.04 to 4.68	0.46 0.17 to 1.16	0.43 0.05 to 3.06	0.41 0.08 to 2.06	0.40 0.02 to 9.00	0.37 0.07 to 1.80	0.37 0.16 to 0.84	0.37 0.08 to 1.99	0.36 0.08 to 1.45	0.31 0.03 to 3.09	0.30 0.04 to 1.73	0.27 0.03 to 1.74	0.24 0.03 to 1.47	0.23 0.10 to 0.48	0.22 0.09 to 0.49	0.22 0.08 to 0.60	0.21 0.03 to 1.41	0.19 0.05 to 0.64	0.18 0.03 to 0.95	0.15 0.01 to 1.44	0.15 0.03 to 0.62	0.13 0.02 to 0.69	0.09 0.01 to 0.43
INS_GLARGINE	0.02 0.00 to 0.19	INS_GLARGINE	0.23 0.00 to 17.23	0.19 0.00 to 14.00	0.17 0.00 to 15.22	0.16 0.00 to 11.99	0.07 0.00 to 4.25	0.08 0.00 to 1.24	0.04 0.00 to 0.45	0.03 0.00 to 4.46	0.02 0.00 to 4.80	0.02 0.00 to 5.11	0.03 0.00 to 0.46	0.02 0.00 to 4.69	0.02 0.00 to 4.84	0.01 0.00 to 0.30	0.01 0.00 to 0.70	0.01 0.00 to 0.28	0.01 0.00 to 0.52	0.01 0.00 to 0.50	0.01 0.00 to 0.19	0.01 0.00 to 0.13	0.01 0.00 to 0.13	0.01 0.00 to 0.15	0.01 0.00 to 0.11	0.01 0.00 to 0.16	0.01 0.00 to 0.12	0.01 0.00 to 0.35	0.01 0.00 to 0.11	0.01 0.00 to 0.08	0.01 0.00 to 0.12	0.01 0.00 to 0.10	0.00 0.00 to 0.15	0.00 0.00 to 0.08	0.00 0.00 to 0.10	0.00 0.00 to 0.09	0.00 0.00 to 0.05	0.00 0.00 to 0.05	0.00 0.00 to 0.05	0.00 0.00 to 0.08	0.00 0.00 to 0.05	0.00 0.00 to 0.05	0.00 0.00 to 0.07	0.00 0.00 to 0.04	0.00 0.00 to 0.04	0.00 0.00 to 0.02
INS_ASPART	0.07 0.00 to 0.80	4.34 0.06 to 274	INS_ASPART	0.82 0.01 to 70.77	0.74 0.01 to 68.02	0.69 0.01 to 57.28	0.32 0.00 to 20.02	0.34 0.01 to 4.66	0.17 0.00 to 3.90	0.11 0.00 to 21.39	0.10 0.00 to 22.10	0.11 0.00 to 21.67	0.09 0.00 to 6.17	0.09 0.00 to 19.98	0.09 0.00 to 18.69	0.06 0.00 to 1.34	0.05 0.00 to 3.53	0.05 0.00 to 1.16	0.04 0.00 to 2.47	0.05 0.00 to 2.07	0.04 0.00 to 0.90	0.05 0.00 to 1.11	0.04 0.00 to 0.49	0.03 0.00 to 0.97	0.03 0.00 to 0.43	0.03 0.00 to 0.74	0.03 0.00 to 0.49	0.03 0.00 to 1.37	0.03 0.00 to 0.45	0.03 0.00 to 0.29	0.03 0.00 to 0.46	0.02 0.00 to 0.41	0.02 0.00 to 0.63	0.02 0.00 to 0.45	0.02 0.00 to 0.43	0.02 0.00 to 0.40	0.02 0.00 to 0.17	0.02 0.00 to 0.19	0.02 0.00 to 0.21	0.01 0.00 to 0.28	0.01 0.00 to 0.21	0.01 0.00 to 0.27	0.01 0.00 to 0.29	0.01 0.00 to 0.18	0.01 0.00 to 0.18	0.01 0.00 to 0.12
OTHER_ACTIVE_sulfonylurea	0.09 0.00 to 1.05	5.40 0.07 to 322	1.22 0.01 to 95.65	OTHER_ACTIVE_sulfonylurea	0.90 0.01 to 72.97	0.83 0.01 to 63.51	0.37 0.00 to 27.13	0.41 0.01 to 6.04	0.21 0.00 to 4.54	0.15 0.00 to 26.16	0.13 0.00 to 26.90	0.13 0.00 to 29.36	0.12 0.00 to 7.57	0.11 0.00 to 24.16	0.11 0.00 to 28.14	0.07 0.00 to 1.68	0.06 0.00 to 4.35	0.06 0.00 to 1.72	0.05 0.00 to 2.96	0.05 0.00 to 2.74	0.06 0.00 to 1.10	0.06 0.00 to 1.49	0.05 0.00 to 0.63	0.04 0.00 to 1.18	0.04 0.00 to 0.57	0.03 0.00 to 0.97	0.04 0.00 to 0.66	0.03 0.00 to 1.83	0.03 0.00 to 0.59	0.03 0.00 to 0.42	0.03 0.00 to 0.59	0.03 0.00 to 0.53	0.02 0.00 to 0.86	0.02 0.00 to 0.55	0.02 0.00 to 0.59	0.02 0.00 to 0.51	0.02 0.00 to 0.25	0.02 0.00 to 0.21	0.02 0.00 to 0.24	0.02 0.00 to 0.40	0.02 0.00 to 0.27	0.01 0.00 to 0.32	0.01 0.00 to 0.39	0.01 0.00 to 0.24	0.01 0.00 to 0.24	0.01 0.00 to 0.15
DAPAGLIFLOZIN	0.09 0.00 to 1.77	5.99 0.07 to 434	1.35 0.01 to 139	1.12 0.01 to 113	DAPAGLIFLOZIN	0.89 0.01 to 107	0.42 0.00 to 39.24	0.44 0.01 to 11.11	0.22 0.00 to 7.36	0.16 0.00 to 36.43	0.14 0.00 to 36.78	0.14 0.00 to 36.66	0.13 0.00 to 10.65	0.13 0.00 to 33.67	0.12 0.00 to 34.13	0.08 0.00 to 2.65	0.07 0.00 to 6.11	0.06 0.00 to 2.63	0.06 0.00 to 4.11	0.06 0.00 to 3.70	0.06 0.00 to 1.84	0.06 0.00 to 2.37	0.05 0.00 to 1.20	0.04 0.00 to 1.85	0.04 0.00 to 0.97	0.04 0.00 to 0.56	0.04 0.00 to 1.11	0.04 0.00 to 2.91	0.03 0.00 to 0.98	0.03 0.00 to 0.76	0.03 0.00 to 1.06	0.03 0.00 to 0.96	0.03 0.00 to 1.25	0.03 0.00 to 0.78	0.03 0.00 to 0.34	0.02 0.00 to 0.30	0.02 0.00 to 0.47	0.02 0.00 to 0.45	0.02 0.00 to 0.49	0.02 0.00 to 0.66	0.02 0.00 to 0.44	0.02 0.00 to 0.50	0.01 0.00 to 0.64	0.01 0.00 to 0.38	0.01 0.00 to 0.38	0.01 0.00 to 0.24
OTHER_ACTIVE_additional_OAD	0.11 0.00 to 1.31	6.35 0.08 to 443	1.45 0.02 to 118	1.21 0.02 to 96.66	1.12 0.01 to 106	OTHER_ACTIVE_additional_OAD	0.49 0.00 to 31.04	0.51 0.01 to 7.55	0.25 0.00 to 5.52	0.17 0.00 to 33.39	0.16 0.00 to 32.26	0.15 0.00 to 38.55	0.13 0.00 to 9.62	0.13 0.00 to 29.64	0.13 0.00 to 29.64	0.08 0.00 to 2.19	0.08 0.00 to 4.84	0.07 0.00 to 1.73	0.06 0.00 to 3.30	0.07 0.00 to 3.41	0.07 0.00 to 1.38	0.07 0.00 to 1.80	0.06 0.00 to 0.76	0.05 0.00 to 1.43	0.05 0.00 to 0.71	0.04 0.00 to 1.22	0.04 0.00 to 0.85	0.04 0.00 to 2.47	0.04 0.00 to 0.74	0.04 0.00 to 0.45	0.04 0.00 to 0.84	0.04 0.00 to 0.67	0.03 0.00 to 0.99	0.03 0.00 to 0.67	0.03 0.00 to 0.74	0.02 0.00 to 0.62	0.02 0.00 to 0.28	0.02 0.00 to 0.31	0.02 0.00 to 0.34	0.02 0.00 to 0.46	0.02 0.00 to 0.35	0.02 0.00 to 0.41	0.02 0.00 to 0.49	0.01 0.00 to 0.29	0.01 0.00 to 0.30	0.01 0.00 to 0.18
OTHER_ACTIVE_investigator_choice_oral_drug	0.21 0.01 to 4.79	13.74 0.24 to 1247	3.10 0.05 to 338	2.67 0.04 to 239	2.40 0.03 to 263	2.06 0.03 to 273	OTHER_ACTIVE_investigator_choice_oral_drug	1.00 0.03 to 29.64	0.51 0.01 to 18.87	0.38 0.00 to 82.06	0.33 0.00 to 78.45	0.33 0.00 to 93.61	0.29 0.00 to 24.58	0.30 0.00 to 86.31	0.28 0.00 to 83.41	0.17 0.00 to 6.88	0.16 0.07 to 0.39	0.15 0.00 to 6.26	0.14 0.00 to 9.46	0.14 0.00 to 9.25	0.14 0.00 to 4.66	0.14 0.00 to 5.87	0.12 0.00 to 2.95	0.10 0.00 to 4.45	0.10 0.00 to 2.42	0.09 0.00 to 3.55	0.09 0.00 to 3.00	0.08 0.00 to 6.86	0.08 0.00 to 2.55	0.08 0.00 to 1.87	0.08 0.00 to 2.47	0.08 0.00 to 2.30	0.06 0.00 to 3.03	0.06 0.00 to 2.35	0.06 0.00 to 2.15	0.05 0.00 to 1.89	0.05 0.00 to 1.16	0.05 0.00 to 1.16	0.05 0.00 to 1.18	0.04 0.00 to 1.68	0.04 0.00 to 1.08	0.04 0.00 to 1.30	0.03 0.00 to 1.46	0.03 0.00 to 0.91	0.03 0.00 to 0.89	0.02 0.00 to 0.62
SITAGLIPTIN	0.21 0.06 to 0.64	12.58 0.81 to 417	2.91 0.21 to 124	2.42 0.17 to 111	2.28 0.09 to 109	1.95 0.13 to 87.18	1.00 0.03 to 30.44	SITAGLIPTIN	0.50 0.07 to 4.57	0.37 0.01 to 37.37	0.34 0.00 to 38.50	0.33 0.00 to 42.54	0.30 0.01 to 8.94	0.29 0.00 to 39.72	0.28 0.00 to 35.58	0.17 0.02 to 1.54	0.16 0.01 to 4.92	0.14 0.02 to 1.47	0.14 0.01 to 3.50	0.14 0.01 to 3.25	0.14 0.02 to 0.98	0.14 0.01 to 1.38	0.12 0.03 to 0.40	0.10 0.01 to 1.28	0.10 0.02 to 0.41	0.09 0.01 to 0.89	0.09 0.02 to 0.28	0.08 0.00 to 2.32	0.08 0.02 to 0.24	0.08 0.02 to 0.21	0.08 0.01 to 0.52	0.08 0.01 to 0.45	0.06 0.00 to 0.85	0.06 0.01 to 0.50	0.06 0.00 to 0.52	0.05 0.00 to 0.45	0.05 0.01 to 0.13	0.05 0.01 to 0.15	0.05 0.01 to 0.18	0.04 0.01 to 0.35	0.04 0.01 to 0.22	0.04 0.00 to 0.30	0.03 0.00 to 0.40	0.03 0.00 to 0.18	0.03 0.00 to 0.19	0.02 0.00 to 0.13
DULA_SC_0p75MG_QW	0.42 0.06 to 2.26	23.81 2.21 to 829	5.96 0.26 to 289	4.84 0.22 to 249	4.49 0.14 to 255	4.00 0.18 to 228	1.97 0.05 to 73.53	1.99 0.22 to 15.18	DULA_SC_0p75MG_QW	0.73 0.01 to 87.77	0.66 0.01 to 99.08	0.65 0.01 to 101	0.58 0.01 to 19.93	0.58 0.01 to 77.50	0.54 0.01 to 86.09	0.34 0.03 to 3.80	0.31 0.01 to 12.33	0.29 0.02 to 4.64	0.28 0.01 to 8.41	0.28 0.01 to 7.08	0.27 0.02 to 2.68	0.28 0.07 to 0.90	0.24 0.03 to 1.53	0.20 0.02 to 1.13	0.19 0.02 to 1.33	0.18 0.01 to 2.34	0.17 0.01 to 1.64	0.16 0.00 to 5.42	0.15 0.01 to 1.46	0.15 0.02 to 0.91	0.15 0.02 to 1.33	0.15 0.01 to 1.31	0.12 0.01 to 2.15	0.12 0.01 to 1.31	0.11 0.01 to 1.47	0.10 0.01 to 1.23	0.10 0.01 to 0.56	0.09 0.01 to 0.55	0.09 0.01 to 0.53	0.09 0.01 to 1.03	0.08 0.01 to 0.61	0.07 0.00 to 0.75	0.06 0.00 to 1.05	0.06 0.00 to 0.57	0.05 0.00 to 0.57	0.04 0.00 to 0.38
STANDARD_CARE	0.58 0.01 to 31.91	37.08 0.22 to 6088	8.76 0.05 to 1701	6.84 0.04 to 1628	6.22 0.03 to 1536	5.86 0.03 to 1307	2.65 0.01 to 466	2.70 0.03 to 196	1.37 0.01 to 126	STANDARD_CARE	0.91 0.00 to 411	0.86 0.00 to 442	0.79 0.00 to 136	0.80 0.00 to 321	0.74 0.00 to 392	0.46 0.00 to 39.58	0.43 0.00 to 76.73	0.39 0.00 to 39.66	0.37 0.00 to 55.91	0.38 0.00 to 50.69	0.37 0.00 to 28.07	0.36 0.00 to 38.63	0.32 0.00 to 19.90	0.26 0.00 to 27.43	0.26 0.00 to 16.36	0.25 0.00 to 20.24	0.23 0.00 to 17.39	0.22 0.00 to 36.89	0.21 0.00 to 15.36	0.21 0.00 to 13.38	0.21 0.00 to 16.45	0.21 0.00 to 13.90	0.17 0.00 to 17.99	0.16 0.00 to 13.35	0.15 0.00 to 12.38	0.13 0.00 to 11.20	0.13 0.00 to 8.48	0.13 0.00 to 7.63	0.13 0.00 to 7.62	0.11 0.00 to 11.41	0.11 0.00 to 6.91	0.10 0.00 to 8.08	0.09 0.00 to 8.63	0.08 0.00 to 5.36	0.08 0.00 to 5.13	0.05 0.00 to 3.96
DULA_SC_0p25MG_QW	0.63 0.01 to 47.95	40.75 0.21 to 7944	9.67 0.05 to 2216	7.58 0.04 to 1874	7.21 0.03 to 1631	6.36 0.03 to 1572	3.00 0.01 to 632	2.96 0.03 to 265	1.51 0.01 to 164	1.10 0.00 to 682	DULA_SC_0p25MG_QW	0.95 0.00 to 539	0.81 0.00 to 189	0.88 0.00 to 477	0.83 0.00 to 500	0.50 0.00 to 55.58	0.49 0.00 to 102	0.44 0.00 to 51.77	0.42 0.00 to 81.59	0.40 0.00 to 71.59	0.39 0.00 to 39.90	0.40 0.00 to 48.49	0.35 0.00 to 28.77	0.28 0.00 to 35.37	0.28 0.00 to 24.34	0.26 0.00 to 30.20	0.25 0.00 to 26.22	0.24 0.00 to 47.24	0.22 0.00 to 23.59	0.23 0.00 to 18.15	0.23 0.00 to 21.85	0.22 0.00 to 20.98	0.18 0.00 to 24.82	0.17 0.00 to 18.73	0.16 0.00 to 17.55	0.14 0.00 to 16.01	0.14 0.00 to 11.35	0.13 0.00 to 10.89	0.13 0.00 to 11.52	0.13 0.00 to 13.46	0.11 0.00 to 10.40	0.11 0.00 to 10.48	0.09 0.00 to 11.70	0.09 0.00 to 8.41	0.08 0.00 to 8.29	0.05 0.00 to 5.55
DULA_SC_0p5MG_QW	0.63 0.01 to 49.51	42.07 0.20 to 8135	9.22 0.05 to 2480	7.79 0.03 to 2054	6.99 0.03 to 1642	6.51 0.03 to 1813	2.99 0.01 to 599	3.01 0.02 to 256	1.55 0.01 to 176	1.16 0.00 to 593	1.05 0.00 to 503	DULA_SC_0p5MG_QW	0.84 0.00 to 186	0.89 0.00 to 607	0.84 0.00 to 539	0.52 0.00 to 62.90	0.49 0.00 to 98.38	0.44 0.00 to 50.40	0.43 0.00 to 80.33	0.43 0.00 to 76.09	0.41 0.00 to 39.48	0.42 0.00 to 51.63	0.36 0.00 to 29.60	0.28 0.00 to 38.55	0.29 0.00 to 24.69	0.26 0.00 to 34.17	0.26 0.00 to 25.49	0.24 0.00 to 51.43	0.23 0.00 to 23.17	0.23 0.00 to 19.25	0.24 0.00 to 25.42	0.23 0.00 to 20.52	0.18 0.00 to 27.60	0.18 0.00 to 19.83	0.16 0.00 to 21.94	0.15 0.00 to 18.92	0.14 0.00 to 12.42	0.14 0.00 to 11.72	0.14 0.00 to 11.91	0.13 0.00 to 14.95	0.12 0.00 to 10.35	0.11 0.00 to 11.05	0.09 0.00 to 12.73	0.09 0.00 to 8.63	0.08 0.00 to 8.70	0.05 0.00 to 5.47
IGLARLIXI2_SC_TIT_QD	0.70 0.03 to 23.59	39.98 2.16 to 3447	10.80 0.16 to 1457	8.67 0.13 to 1216	7.83 0.09 to 1201	7.49 0.10 to 1132	3.40 0.04 to 366	3.39 0.11 to 134	1.72 0.05 to 85.74	1.27 0.01 to 389	1.23 0.01 to 356	1.19 0.01 to 364	IGLARLIXI2_SC_TIT_QD	1.03 0.01 to 392	1.00 0.00 to 401	0.58 0.02 to 31.40	0.56 0.01 to 59.13	0.51 0.01 to 30.11	0.47 0.01 to 54.08	0.48 0.01 to 46.73	0.46 0.01 to 23.01	0.47 0.01 to 26.50	0.39 0.01 to 15.35	0.33 0.01 to 21.72	0.32 0.01 to 11.71	0.30 0.01 to 16.49	0.29 0.01 to 13.44	0.28 0.00 to 29.35	0.26 0.01 to 12.64	0.26 0.01 to 10.03	0.26 0.01 to 13.01	0.25 0.01 to 10.87	0.21 0.00 to 15.15	0.20 0.01 to 10.13	0.18 0.00 to 10.12	0.16 0.00 to 8.36	0.16 0.01 to 5.86	0.15 0.01 to 5.65	0.15 0.01 to 6.15	0.15 0.00 to 7.82	0.13 0.00 to 5.57	0.12 0.00 to 6.22	0.11 0.00 to 7.02	0.10 0.00 to 4.60	0.09 0.00 to 4.58	0.06 0.00 to 2.99
METFORMIN	0.71 0.01 to 47.85	44.70 0.21 to 8907	11.06 0.05 to 2432	8.98 0.04 to 1912	7.86 0.03 to 2047	7.48 0.03 to 2031	3.31 0.01 to 763	3.44 0.03 to 287	1.74 0.01 to 171	1.26 0.00 to 576	1.14 0.00 to 565	1.13 0.00 to 600	0.97 0.00 to 181	METFORMIN	0.97 0.00 to 530	0.58 0.00 to 69.04	0.53 0.00 to 126	0.52 0.00 to 59.77	0.47 0.00 to 89.41	0.46 0.00 to 76.20	0.46 0.00 to 44.27	0.46 0.00 to 48.04	0.40 0.00 to 29.35	0.31 0.00 to 40.02	0.32 0.00 to 25.64	0.30 0.00 to 35.13	0.29 0.00 to 27.02	0.28 0.00 to 58.58	0.26 0.00 to 24.35	0.26 0.00 to 19.09	0.27 0.00 to 27.44	0.25 0.00 to 24.33	0.21 0.00 to 27.12	0.20 0.00 to 19.36	0.18 0.00 to 20.58	0.16 0.00 to 18.57	0.16 0.00 to 11.51	0.16 0.00 to 11.37	0.16 0.00 to 12.02	0.15 0.00 to 14.46	0.13 0.00 to 10.88	0.12 0.00 to 12.31	0.11 0.00 to 13.42	0.10 0.00 to 9.26	0.09 0.00 to 8.65	0.06 0.00 to 5.86
LIRAMETF_SC_1p2-1500MG_QD	0.74 0.01 to 52.55	48.18 0.21 to 9383	11.43 0.05 to 2420	9.49 0.04 to 2030	8.13 0.03 to 1990	7.81 0.03 to 1834	3.52 0.01 to 672	3.56 0.03 to 298	1.84 0.01 to 186	1.34 0.00 to 659	1.20 0.00 to 594	1.19 0.00 to 561	1.00 0.00 to 249	1.04 0.00 to 543	LIRAMETF_SC_1p2-1500MG_QD	0.60 0.00 to 70.73	0.57 0.00 to 109	0.51 0.00 to 55.81	0.49 0.00 to 86.32	0.50 0.00 to 73.80	0.48 0.00 to 42.23	0.49 0.00 to 53.49	0.43 0.00 to 31.59	0.34 0.00 to 42.22	0.33 0.00 to 27.20	0.31 0.00 to 36.10	0.29 0.00 to 27.29	0.27 0.00 to 58.29	0.27 0.00 to 24.64	0.27 0.00 to 20.47	0.28 0.00 to 23.55	0.26 0.00 to 21.83	0.22 0.00 to 27.66	0.21 0.00 to 22.08	0.19 0.00 to 20.74	0.18 0.00 to 18.44	0.17 0.00 to 11.87	0.16 0.00 to 12.33	0.16 0.00 to 11.79	0.16 0.00 to 14.80	0.14 0.00 to 10.92	0.12 0.00 to 13.89	0.11 0.00 to 13.65	0.11 0.00 to 9.67	0.10 0.00 to 9.06	0.06 0.00 to 5.88
SEMA_PO_3MG_QD	1.26 0.17 to 7.04	77.99 3.32 to 3242	18.09 0.75 to 923	14.28 0.60 to 744	13.31 0.38 to 747	12.27 0.46 to 679	5.97 0.15 to 223	5.98 0.65 to 45.18	2.92 0.26 to 35.43	2.18 0.03 to 238	2.00 0.02 to 282	1.91 0.02 to 292	1.72 0.03 to 65.85	1.74 0.01 to 255	1.68 0.01 to 270	SEMA_PO_3MG_QD	0.98 0.02 to 35.96	0.88 0.06 to 13.36	0.83 0.02 to 28.07	0.82 0.03 to 23.02	0.83 0.07 to 8.38	0.83 0.06 to 11.32	0.72 0.09 to 4.49	0.57 0.03 to 9.65	0.57 0.06 to 4.06	0.53 0.03 to 7.23	0.52 0.04 to 5.15	0.49 0.01 to 16.80	0.46 0.04 to 4.51	0.46 0.05 to 2.92	0.47 0.06 to 2.73	0.46 0.03 to 4.11	0.37 0.02 to 7.00	0.36 0.02 to 4.23	0.33 0.02 to 4.41	0.30 0.02 to 3.85	0.29 0.03 to 1.72	0.28 0.04 to 1.45	0.28 0.04 to 1.26	0.26 0.02 to 3.21	0.24 0.02 to 1.90	0.22 0.01 to 2.56	0.19 0.01 to 3.12	0.18 0.01 to 1.75	0.16 0.01 to 1.83	0.11 0.01 to 1.19
LIRA_SC_FLEX_0p6-1p2-1p8_QD	1.30 0.05 to 26.89	83.13 1.42 to 7710	19.48 0.28 to 2166	16.02 0.23 to 1445	14.55 0.16 to 1616	12.87 0.21 to 1669	6.12 2.56 to 15.19	6.31 0.20 to 168	3.19 0.08 to 110	2.32 0.01 to 467	2.06 0.01 to 497	2.05 0.01 to 577	1.80 0.02 to 150	1.89 0.01 to 510	1.74 0.01 to 513	1.03 0.03 to 40.17	LIRA_SC_FLEX_0p6-1p2-1p8_QD	0.93 0.02 to 37.02	0.89 0.01 to 56.13	0.86 0.01 to 55.77	0.86 0.02 to 26.91	0.88 0.02 to 35.20	0.74 0.03 to 18.27	0.60 0.01 to 28.19	0.60 0.02 to 14.56	0.55 0.01 to 20.39	0.53 0.02 to 17.57	0.50 0.01 to 39.06	0.48 0.01 to 15.75	0.48 0.02 to 11.43	0.49 0.01 to 15.77	0.49 0.01 to 14.04	0.39 0.01 to 17.73	0.38 0.01 to 13.74	0.34 0.01 to 13.56	0.31 0.01 to 12.09	0.30 0.01 to 6.85	0.28 0.01 to 6.63	0.28 0.01 to 6.92	0.27 0.01 to 9.92	0.24 0.01 to 6.29	0.23 0.01 to 7.71	0.19 0.00 to 8.11	0.19 0.00 to 5.49	0.17 0.00 to 5.08	0.11 0.00 to 3.82
TIRZ_SC_5MG_QW	1.43 0.16 to 9.76	89.27 3.57 to 3895	20.59 0.86 to 1095	16.75 0.58 to 1079	15.45 0.38 to 980	13.53 0.58 to 824	6.79 0.16 to 282	6.92 0.68 to 56.07	3.42 0.22 to 50.00	2.59 0.03 to 363	2.30 0.02 to 328	2.29 0.02 to 354	1.96 0.03 to 80.07	1.94 0.02 to 296	1.95 0.02 to 352	1.14 0.07 to 17.05	1.07 0.03 to 48.13	TIRZ_SC_5MG_QW	0.93 0.02 to 32.69	0.92 0.03 to 30.03	0.94 0.06 to 11.43	0.93 0.05 to 15.30	0.83 0.09 to 5.60	0.65 0.03 to 13.52	0.64 0.06 to 5.68	0.59 0.03 to 9.20	0.58 0.04 to 6.29	0.55 0.01 to 22.39	0.52 0.04 to 5.52	0.53 0.06 to 3.13	0.53 0.04 to 6.53	0.51 0.04 to 5.74	0.42 0.02 to 9.22	0.41 0.02 to 5.98	0.37 0.02 to 5.42	0.33 0.02 to 4.70	0.33 0.04 to 1.98	0.32 0.03 to 2.25	0.31 0.03 to 2.62	0.30 0.02 to 3.81	0.27 0.02 to 2.69	0.24 0.01 to 3.49	0.21 0.01 to 4.19	0.20 0.01 to 2.35	0.18 0.01 to 2.37	0.12 0.01 to 1.56
TIRZ_SC_15MG_QW	1.47 0.08 to 31.64	98.30 1.93 to 7824	23.10 0.41 to 2087	18.27 0.34 to 1719	16.68 0.24 to 1855	15.47 0.30 to 1683	7.04 0.11 to 660	6.99 0.29 to 198	3.57 0.12 to 129	2.72 0.02 to 599	2.38 0.01 to 647	2.34 0.01 to 684	2.11 0.02 to 174	2.15 0.01 to 529	2.04 0.01 to 562	1.21 0.04 to 47.40	1.13 0.02 to 103	1.07 0.03 to 43.74	TIRZ_SC_15MG_QW	0.98 0.02 to 58.84	0.95 0.03 to 29.62	0.98 0.03 to 36.14	0.84 0.04 to 19.58	0.67 0.01 to 32.15	0.67 0.03 to 16.44	0.62 0.02 to 25.64	0.61 0.02 to 19.18	0.59 0.02 to 14.71	0.55 0.02 to 17.20	0.54 0.03 to 12.78	0.55 0.02 to 18.42	0.53 0.02 to 15.50	0.44 0.01 to 20.16	0.42 0.01 to 15.37	0.39 0.01 to 15.02	0.35 0.01 to 12.83	0.33 0.02 to 7.71	0.32 0.01 to 7.46	0.32 0.01 to 7.95	0.31 0.01 to 11.09	0.27 0.01 to 8.21	0.26 0.01 to 8.74	0.22 0.01 to 8.99	0.21 0.01 to 5.93	0.19 0.01 to 5.93	0.13 0.00 to 4.23
DANU_PO_120MG_BID	1.49 0.08 to 21.90	97.64 1.99 to 6937	22.15 0.48 to 1817	18.25 0.37 to 1598	16.77 0.27 to 1353	15.19 0.29 to 1390	7.13 0.11 to 450	7.18 0.31 to 144	3.61 0.14 to 93.28	2.63 0.02 to 506	2.52 0.01 to 496	2.33 0.01 to 484	2.08 0.02 to 138	2.16 0.01 to 400	1.99 0.01 to 450	1.23 0.04 to 32.56	1.16 0.02 to 71.36	1.08 0.03 to 31.87	1.02 0.02 to 53.18	DANU_PO_120MG_BID	0.99 0.03 to 21.07	1.02 0.03 to 28.92	0.87 0.04 to 14.75	0.69 0.02 to 23.46	0.69 0.03 to 12.08	0.63 0.02 to 16.70	0.61 0.02 to 13.67	0.58 0.01 to 38.45	0.56 0.02 to 12.68	0.56 0.03 to 9.17	0.56 0.02 to 12.95	0.54 0.02 to 11.26	0.47 0.02 to 5.54	0.43 0.01 to 10.44	0.41 0.01 to 10.00	0.35 0.01 to 8.78	0.34 0.02 to 5.57	0.33 0.02 to 5.29	0.33 0.02 to 5.56	0.31 0.01 to 7.87	0.28 0.01 to 5.70	0.26 0.01 to 6.27	0.24 0.01 to 2.32	0.21 0.01 to 4.55	0.19 0.01 to 4.71	0.13 0.00 to 2.96
EFPE_SC_2MG_QW	1.53 0.32 to 7.36	95.03 5.29 to 3546	22.40 1.11 to 991	17.76 0.91 to 874	16.37 0.54 to 888	14.72 0.72 to 792	7.31 0.21 to 266	7.25 1.02 to 54.51	3.66 0.37 to 43.55	2.67 0.04 to 327	2.53 0.03 to 329	2.44 0.03 to 333	2.16 0.04 to 75.42	2.16 0.02 to 314	2.06 0.02 to 333	1.21 0.12 to 15.00	1.16 0.04 to 44.59	1.07 0.09 to 15.77	1.05 0.03 to 28.94	1.01 0.05 to 30.28	EFPE_SC_2MG_QW	1.00 0.09 to 14.02	0.89 0.14 to 5.37	0.71 0.04 to 11.07	0.70 0.11 to 4.30	0.66 0.04 to 8.15	0.63 0.07 to 5.72	0.61 0.02 to 20.35	0.56 0.06 to 5.15	0.56 0.09 to 3.25	0.58 0.06 to 5.79	0.56 0.13 to 2.05	0.47 0.02 to 7.61	0.44 0.04 to 4.56	0.41 0.03 to 4.66	0.36 0.02 to 4.03	0.35 0.06 to 2.00	0.34 0.05 to 1.97	0.33 0.05 to 2.10	0.32 0.03 to 3.56	0.29 0.07 to 0.96	0.26 0.02 to 2.60	0.23 0.01 to 3.47	0.22 0.02 to 1.81	0.20 0.02 to 1.83	0.13 0.01 to 1.32
DULA_SC_1p5MG_QW	1.53 0.19 to 10.98	86.51 7.96 to 3168	21.55 0.90 to 1210	17.55 0.67 to 1070	16.61 0.42 to 978	14.80 0.55 to 943	7.01 0.17 to 325	7.21 0.72 to 68.60	3.61 1.11 to 13.66	2.74 0.03 to 346	2.48 0.02 to 375	2.37 0.02 to 410	2.12 0.04 to 78.95	2.18 0.02 to 332	2.04 0.02 to 361	1.21 0.09 to 17.20	1.14 0.03 to 53.60	1.08 0.07 to 18.65	1.02 0.03 to 35.03	0.98 0.03 to 29.11	1.00 0.07 to 11.66	DULA_SC_1p5MG_QW	0.86 0.09 to 7.10	0.69 0.07 to 5.96	0.69 0.07 to 6.19	0.62 0.03 to 10.84	0.62 0.04 to 7.03	0.60 0.01 to 21.89	0.55 0.04 to 6.38	0.56 0.06 to 4.28	0.56 0.05 to 5.94	0.55 0.04 to 5.79	0.45 0.02 to 9.27	0.44 0.03 to 5.67	0.40 0.02 to 6.18	0.36 0.02 to 5.63	0.35 0.04 to 2.65	0.34 0.04 to 2.50	0.34 0.04 to 2.61	0.32 0.02 to 4.23	0.28 0.02 to 2.72	0.27 0.02 to 3.45	0.23 0.01 to 4.19	0.22 0.02 to 2.44	0.19 0.01 to 2.57	0.13 0.01 to 1.65
EXENER_SC_2MG_QW	1.76 0.68 to 4.49	107 7.62 to 3370	24.62 2.05 to 964	19.96 1.59 to 833	19.42 0.83 to 864	16.64 1.32 to 736	8.26 0.34 to 242	8.21 2.51 to 32.06	4.19 0.65 to 33.79	3.12 0.05 to 311	2.85 0.03 to 306	2.76 0.03 to 364	2.54 0.07 to 69.33	2.47 0.03 to 278	2.35 0.03 to 298	1.38 0.22 to 11.63	1.35 0.05 to 39.28	1.21 0.18 to 11.55	1.19 0.05 to 26.28	1.15 0.07 to 24.51	1.13 0.19 to 7.08	1.16 0.14 to 10.98	EXENER_SC_2MG_QW	0.81 0.06 to 9.27	0.79 0.21 to 3.10	0.75 0.07 to 6.83	0.72 0.13 to 4.00	0.69 0.03 to 17.82	0.65 0.12 to 3.49	0.65 0.26 to 1.54	0.65 0.12 to 3.78	0.64 0.11 to 3.38	0.54 0.04 to 6.94	0.51 0.06 to 3.92	0.47 0.05 to 3.80	0.42 0.04 to 3.35	0.40 0.17 to 0.85	0.39 0.16 to 0.89	0.38 0.13 to 1.14	0.36 0.05 to 2.46	0.33 0.06 to 1.57	0.31 0.04 to 2.10	0.27 0.02 to 2.96	0.26 0.04 to 1.42	0.23 0.03 to 1.54	0.15 0.02 to 1.01
LIRA_SC_0p9MG_QD	2.16 0.21 to 23.65	135 6.83 to 6326	31.11 1.03 to 2149	26.17 0.85 to 1784	24.08 0.54 to 1843	21.86 0.70 to 1633	10.43 0.22 to 512	10.35 0.78 to 141	5.06 0.89 to 42.07	3.88 0.04 to 635	3.52 0.03 to 613	3.53 0.03 to 684	3.05 0.05 to 157	3.18 0.02 to 545	2.97 0.02 to 608	1.77 0.10 to 36.00	1.67 0.04 to 86.94	1.55 0.07 to 39.74	1.49 0.03 to 70.52	1.46 0.04 to 55.26	1.41 0.09 to 24.54	1.44 0.17 to 14.67	1.24 0.11 to 15.77	LIRA_SC_0p9MG_QD	0.99 0.08 to 13.07	0.93 0.04 to 19.61	0.89 0.06 to 14.87	0.85 0.02 to 42.20	0.80 0.05 to 13.44	0.80 0.07 to 9.38	0.80 0.06 to 13.40	0.78 0.05 to 11.82	0.66 0.02 to 17.66	0.64 0.03 to 11.72	0.57 0.02 to 12.35	0.51 0.02 to 10.75	0.49 0.04 to 5.80	0.48 0.04 to 5.69	0.47 0.04 to 5.80	0.45 0.02 to 8.95	0.41 0.03 to 5.79	0.38 0.02 to 7.13	0.33 0.01 to 8.47	0.31 0.02 to 5.16	0.28 0.02 to 5.12	0.19 0.01 to 3.44
SEMA_SC_2p4MG_QW	2.19 0.86 to 5.92	135 9.29 to 4417	31.13 2.32 to 1203	25.35 1.76 to 1118	24.04 1.03 to 1071	20.92 1.42 to 995	10.32 0.41 to 312	10.38 2.45 to 50.31	5.25 0.75 to 45.81	3.82 0.06 to 391	3.53 0.04 to 409	3.46 0.04 to 462	3.17 0.09 to 88.27	3.11 0.04 to 388	2.99 0.04 to 390	1.75 0.25 to 16.47	1.67 0.07 to 52.29	1.55 0.18 to 15.60	1.50 0.06 to 32.90	1.45 0.08 to 29.43	1.43 0.23 to 9.19	1.45 0.16 to 14.76	1.26 0.32 to 4.69	1.01 0.08 to 12.75	SEMA_SC_2p4MG_QW	0.95 0.08 to 8.43	0.92 0.14 to 5.99	0.89 0.03 to 22.26	0.82 0.13 to 5.37	0.81 0.22 to 2.87	0.80 0.13 to 5.72	0.80 0.14 to 4.10	0.67 0.05 to 8.38	0.64 0.07 to 5.01	0.58 0.05 to 5.08	0.53 0.05 to 4.10	0.50 0.14 to 1.74	0.49 0.13 to 1.72	0.48 0.12 to 1.99	0.46 0.06 to 3.97	0.41 0.08 to 1.97	0.39 0.05 to 2.71	0.33 0.03 to 3.78	0.32 0.04 to 1.83	0.29 0.04 to 1.96	0.19 0.02 to 1.28
SAFIGL_PO_30MG_QD	2.32 0.33 to 20.50	150 6.10 to 7201	35.10 1.35 to 2148	28.63 1.03 to 1830	23.89 1.77 to 1188	24.00 0.82 to 1619	11.33 0.28 to 573	11.14 1.12 to 137	5.63 0.43 to 98.25	4.05 0.05 to 608	3.83 0.03 to 582	3.91 0.03 to 648	3.39 0.06 to 155	3.34 0.03 to 545	3.26 0.03 to 624	1.89 0.14 to 38.99	1.81 0.05 to 87.78	1.68 0.11 to 33.75	1.61 0.04 to 61.99	1.58 0.06 to 53.61	1.52 0.12 to 23.76	1.60 0.09 to 30.67	1.34 0.15 to 14.31	1.08 0.05 to 26.24	1.06 0.12 to 11.93	SAFIGL_PO_30MG_QD	0.97 0.08 to 15.02	0.91 0.02 to 42.85	0.86 0.07 to 12.69	0.86 0.11 to 8.93	0.87 0.07 to 14.20	0.83 0.07 to 12.07	0.72 0.03 to 17.13	0.68 0.04 to 11.07	0.64 0.19 to 1.93	0.56 0.17 to 1.65	0.53 0.07 to 5.43	0.51 0.06 to 5.31	0.51 0.06 to 5.48	0.48 0.03 to 9.34	0.43 0.04 to 5.62	0.41 0.03 to 6.75	0.36 0.02 to 7.98	0.34 0.03 to 4.48	0.31 0.02 to 4.84	0.21 0.01 to 3.22
TASP_SC_10MG_QW	2.45 0.49 to 12.29	150 8.03 to 5781	33.97 2.03 to 1733	28.19 1.51 to 1448	27.14 0.90 to 1350	23.99 1.18 to 1170	11.68 0.33 to 397	11.35 3.54 to 44.95	5.86 0.61 to 68.30	4.28 0.06 to 527	3.99 0.04 to 491	3.84 0.04 to 540	3.44 0.07 to 120	3.43 0.04 to 506	3.42 0.04 to 467	1.93 0.19 to 25.33	1.88 0.06 to 66.62	1.73 0.16 to 22.61	1.64 0.05 to 46.97	1.64 0.07 to 41.34	1.60 0.17 to 14.74	1.62 0.14 to 22.51	1.38 0.25 to 7.66	1.12 0.07 to 18.18	1.09 0.17 to 7.14	1.03 0.07 to 13.30	TASP_SC_10MG_QW	0.95 0.03 to 30.10	0.90 0.44 to 1.85	0.90 0.18 to 4.19	0.90 0.10 to 8.29	0.89 0.10 to 7.29	0.74 0.04 to 12.35	0.70 0.06 to 7.34	0.65 0.04 to 7.62	0.58 0.04 to 6.84	0.56 0.11 to 2.60	0.53 0.10 to 2.83	0.53 0.09 to 3.40	0.50 0.05 to 5.31	0.46 0.05 to 3.40	0.42 0.04 to 4.36	0.37 0.02 to 6.01	0.35 0.03 to 2.96	0.31 0.03 to 3.10	0.21 0.02 to 1.96
TIRZ_SC_12MG_QW	2.51 0.11 to 53.88	166 2.86 to 13324	39.50 0.73 to 3252	30.82 0.55 to 3110	27.95 0.34 to 3223	25.65 0.40 to 2881	12.25 0.15 to 1067	12.12 0.43 to 334	6.16 0.18 to 218	4.65 0.03 to 1058	4.11 0.02 to 977	4.12 0.02 to 1141	3.56 0.03 to 282	3.61 0.02 to 989	3.64 0.02 to 875	2.05 0.06 to 82.98	1.98 0.03 to 174	1.83 0.04 to 70.20	1.70 0.07 to 44.07	1.72 0.03 to 106	1.63 0.05 to 49.37	1.68 0.05 to 67.01	1.45 0.06 to 34.62	1.18 0.02 to 50.41	1.12 0.04 to 30.14	1.10 0.02 to 40.76	1.05 0.03 to 33.84	TIRZ_SC_12MG_QW	0.93 0.03 to 28.61	0.92 0.04 to 22.13	0.94 0.03 to 29.66	0.91 0.03 to 26.44	0.76 0.01 to 35.02	0.73 0.02 to 25.55	0.68 0.01 to 26.53	0.61 0.01 to 22.37	0.57 0.02 to 13.07	0.56 0.02 to 13.17	0.55 0.02 to 14.40	0.54 0.01 to 18.84	0.46 0.02 to 12.85	0.44 0.01 to 15.67	0.39 0.01 to 15.52	0.36 0.01 to 10.61	0.32 0.01 to 10.77	0.22 0.01 to 7.69
TASP_SC_20MG_QW	2.70 0.55 to 13.54	167 8.91 to 6424	37.64 2.20 to 1933	31.22 1.68 to 1706	30.00 1.02 to 1526	26.21 1.36 to 1234	12.75 0.39 to 458	12.61 4.12 to 51.06	6.50 0.69 to 74.68	4.78 0.07 to 574	4.52 0.04 to 556	4.35 0.04 to 601	3.85 0.08 to 132	3.83 0.04 to 551	3.76 0.04 to 549	2.16 0.22 to 27.56	2.07 0.06 to 75.77	1.91 0.18 to 25.35	1.81 0.06 to 52.15	1.80 0.08 to 45.97	1.78 0.19 to 16.84	1.83 0.16 to 24.27	1.53 0.29 to 8.47	1.25 0.07 to 19.24	1.22 0.19 to 7.95	1.16 0.08 to 14.83	1.11 0.54 to 2.28	1.08 0.03 to 36.01	TASP_SC_20MG_QW	0.99 0.20 to 4.80	1.00 0.12 to 9.19	0.98 0.11 to 8.33	0.83 0.04 to 14.02	0.78 0.07 to 8.44	0.72 0.05 to 8.60	0.64 0.04 to 7.71	0.61 0.13 to 3.04	0.59 0.11 to 3.16	0.58 0.10 to 3.61	0.56 0.05 to 6.09	0.51 0.06 to 3.71	0.47 0.04 to 4.78	0.41 0.02 to 6.28	0.39 0.04 to 3.29	0.35 0.03 to 3.51	0.24 0.02 to 2.26
SEMA_SC_0p5MG_QW	2.71 1.19 to 6.38	166 12.26 to 5140	37.49 3.44 to 1409	31.60 2.40 to 1382	29.50 1.32 to 1333	25.01 2.25 to 1110	13.01 0.54 to 359	12.78 4.82 to 42.67	6.54 1.10 to 50.84	4.79 0.07 to 464	4.43 0.06 to 489	4.41 0.05 to 531	3.88 0.10 to 102	3.80 0.05 to 423	3.69 0.05 to 468	2.16 0.34 to 18.31	2.10 0.09 to 60.43	1.89 0.32 to 15.40	1.86 0.08 to 39.31	1.78 0.11 to 36.07	1.78 0.31 to 10.63	1.78 0.23 to 16.65	1.55 0.65 to 3.83	1.25 0.11 to 14.00	1.23 0.35 to 4.48	1.16 0.11 to 9.50	1.11 0.24 to 5.49	1.08 0.05 to 26.88	1.01 0.21 to 4.90	SEMA_SC_0p5MG_QW	1.00 0.19 to 5.78	0.97 0.18 to 4.86	0.82 0.06 to 9.96	0.80 0.10 to 5.73	0.74 0.07 to 5.66	0.65 0.06 to 4.82	0.62 0.39 to 0.96	0.60 0.22 to 1.57	0.59 0.19 to 1.89	0.57 0.09 to 3.79	0.51 0.10 to 2.30	0.48 0.06 to 3.21	0.42 0.03 to 4.66	0.40 0.06 to 2.03	0.36 0.05 to 2.21	0.24 0.03 to 1.51
SEMA_PO_7MG_QD	2.74 0.50 to 12.91	166 8.35 to 6026	39.78 2.15 to 1769	30.94 1.71 to 1421	29.48 0.94 to 1572	26.00 1.19 to 1382	12.75 0.40 to 467	12.87 1.92 to 87.30	6.51 0.75 to 65.39	4.70 0.06 to 522	4.37 0.05 to 576	4.23 0.04 to 637	3.81 0.08 to 126	3.72 0.04 to 514	3.59 0.04 to 570	2.12 0.37 to 16.78	2.05 0.06 to 80.66	1.90 0.15 to 24.21	1.83 0.05 to 54.52	1.78 0.08 to 43.60	1.72 0.17 to 16.61	1.79 0.17 to 21.32	1.55 0.26 to 8.16	1.25 0.07 to 17.70	1.24 0.17 to 7.55	1.15 0.07 to 14.63	1.11 0.12 to 9.70	1.06 0.03 to 34.66	1.00 0.11 to 8.58	1.00 0.17 to 5.39	SEMA_PO_7MG_QD	0.97 0.11 to 8.14	0.80 0.04 to 13.33	0.79 0.06 to 8.16	0.71 0.05 to 8.53	0.65 0.04 to 7.42	0.62 0.11 to 3.15	0.60 0.12 to 2.61	0.59 0.14 to 2.24	0.57 0.05 to 6.04	0.51 0.06 to 3.69	0.47 0.04 to 4.85	0.40 0.02 to 6.10	0.38 0.04 to 3.39	0.34 0.03 to 3.52	0.24 0.02 to 2.23
EFPE_SC_4MG_QW	2.74 0.69 to 12.10	170 10.29 to 6200	40.53 2.45 to 1817	32.30 1.89 to 1540	30.27 1.04 to 1506	26.72 1.49 to 1432	13.13 0.43 to 479	13.06 2.25 to 93.42	6.71 0.76 to 73.49	4.81 0.07 to 541	4.58 0.05 to 574	4.43 0.05 to 576	3.92 0.09 to 122	3.99 0.04 to 532	3.79 0.05 to 529	2.20 0.24 to 28.81	2.06 0.07 to 75.84	1.96 0.17 to 26.54	1.90 0.06 to 50.65	1.85 0.09 to 47.42	1.80 0.49 to 7.79	1.82 0.17 to 23.51	1.56 0.30 to 8.95	1.28 0.08 to 20.11	1.26 0.24 to 7.13	1.20 0.08 to 13.99	1.13 0.14 to 10.13	1.10 0.04 to 33.69	1.02 0.12 to 8.84	1.03 0.21 to 5.50	1.03 0.12 to 9.02	EFPE_SC_4MG_QW	0.84 0.05 to 13.24	0.79 0.08 to 7.77	0.74 0.05 to 8.02	0.67 0.05 to 6.87	0.63 0.13 to 3.38	0.61 0.12 to 3.26	0.60 0.11 to 3.55	0.58 0.06 to 6.19	0.51 0.17 to 1.49	0.48 0.05 to 4.45	0.43 0.02 to 5.78	0.40 0.05 to 3.04	0.36 0.04 to 3.18	0.24 0.02 to 2.13
DANU_PO_40MG_BID	3.27 0.32 to 37.72	214 6.49 to 11812	49.15 1.60 to 3552	40.90 1.16 to 3109	37.45 0.80 to 2714	33.86 1.01 to 2539	15.93 0.33 to 828	15.90 1.17 to 253	8.09 0.47 to 179	5.88 0.06 to 991	5.54 0.04 to 912	5.46 0.04 to 1032	4.72 0.07 to 253	4.82 0.04 to 930	4.62 0.04 to 966	2.69 0.14 to 61.86	2.58 0.06 to 137	2.37 0.11 to 58.67	2.28 0.05 to 97.18	2.13 0.18 to 42.38	2.12 0.13 to 40.06	2.24 0.11 to 57.45	1.86 0.14 to 25.93	1.52 0.06 to 44.38	1.50 0.12 to 21.00	1.40 0.06 to 32.09	1.34 0.08 to 25.98	1.32 0.03 to 72.07	1.21 0.07 to 23.26	1.22 0.10 to 16.74	1.24 0.08 to 24.35	1.19 0.08 to 20.44	DANU_PO_40MG_BID	0.97 0.05 to 19.04	0.88 0.04 to 19.79	0.79 0.03 to 17.25	0.75 0.06 to 9.93	0.72 0.06 to 9.68	0.71 0.06 to 10.24	0.69 0.03 to 15.58	0.61 0.04 to 9.87	0.58 0.03 to 11.42	0.51 0.06 to 3.93	0.48 0.03 to 8.51	0.43 0.02 to 8.68	0.29 0.01 to 5.23
SEMA_SC_2p0MG_QW	3.35 0.58 to 24.16	213 11.86 to 8848	50.35 2.21 to 2868	42.09 1.82 to 2417	37.39 1.28 to 2451	34.50 1.50 to 1913	16.36 0.43 to 740	16.57 2.02 to 155	8.37 0.76 to 128	6.26 0.07 to 772	5.76 0.05 to 811	5.53 0.05 to 943	4.92 0.10 to 185	5.04 0.05 to 757	4.84 0.05 to 761	2.75 0.24 to 40.65	2.64 0.07 to 123	2.46 0.17 to 42.03	2.38 0.07 to 77.73	2.33 0.10 to 73.28	2.26 0.22 to 26.26	2.25 0.18 to 38.82	1.94 0.25 to 16.72	1.56 0.09 to 31.67	1.56 0.20 to 13.89	1.47 0.09 to 23.22	1.43 0.14 to 16.70	1.37 0.04 to 54.84	1.27 0.12 to 14.81	1.26 0.17 to 10.26	1.27 0.12 to 16.63	1.26 0.13 to 13.28	1.03 0.05 to 22.20	SEMA_SC_2p0MG_QW	0.92 0.06 to 13.82	0.81 0.05 to 11.87	0.77 0.11 to 6.18	0.75 0.11 to 6.19	0.73 0.10 to 6.53	0.72 0.05 to 10.95	0.65 0.07 to 6.35	0.61 0.14 to 2.50	0.52 0.03 to 10.26	0.51 0.05 to 5.48	0.45 0.03 to 5.65	0.31 0.07 to 1.07
SAFIGL_PO_60MG_QD	3.72 0.57 to 32.76	239 10.25 to 11719	55.72 2.32 to 3191	46.34 1.69 to 2693	37.93 2.97 to 1768	38.42 1.35 to 2743	17.61 0.46 to 874	17.78 1.93 to 208	9.15 0.68 to 155	6.46 0.08 to 971	6.34 0.06 to 919	6.14 0.05 to 1053	5.42 0.10 to 256	5.43 0.05 to 802	5.19 0.05 to 907	2.99 0.23 to 62.80	2.90 0.07 to 136	2.69 0.18 to 52.26	2.57 0.07 to 98.45	2.45 0.10 to 87.95	2.42 0.21 to 36.21	2.50 0.16 to 49.02	2.11 0.26 to 21.87	1.74 0.08 to 42.21	1.71 0.20 to 18.34	1.57 0.52 to 5.38	1.54 0.13 to 23.59	1.48 0.04 to 69.88	1.39 0.12 to 20.46	1.36 0.18 to 13.47	1.40 0.12 to 21.40	1.36 0.12 to 18.25	1.13 0.05 to 25.98	1.09 0.07 to 17.68	SAFIGL_PO_60MG_QD	0.89 0.31 to 2.46	0.83 0.11 to 8.25	0.81 0.10 to 8.25	0.80 0.10 to 9.03	0.76 0.05 to 14.12	0.67 0.06 to 8.90	0.66 0.04 to 10.38	0.56 0.03 to 12.28	0.54 0.04 to 7.31	0.49 0.04 to 7.24	0.33 0.02 to 4.92
SAFIGL_PO_90MG_QD	4.11 0.68 to 37.29	271 11.51 to 12782	63.22 2.52 to 3450	51.89 1.98 to 3088	42.99 3.36 to 2180	41.78 1.62 to 2913	20.12 0.53 to 978	19.84 2.23 to 244	10.10 0.81 to 178	7.50 0.09 to 1041	7.02 0.06 to 1009	6.83 0.05 to 1118	6.09 0.12 to 276	6.17 0.05 to 925	5.71 0.05 to 1143	3.38 0.26 to 66.23	3.27 0.08 to 157	3.00 0.21 to 62.23	2.85 0.08 to 111	2.83 0.11 to 95.84	2.74 0.25 to 41.42	2.81 0.18 to 55.98	2.40 0.30 to 25.69	1.98 0.09 to 45.00	1.90 0.24 to 21.49	1.78 0.61 to 5.90	1.73 0.15 to 26.92	1.65 0.04 to 76.07	1.57 0.13 to 23.58	1.53 0.21 to 15.91	1.53 0.13 to 23.43	1.49 0.15 to 20.42	1.27 0.06 to 30.89	1.23 0.08 to 20.08	1.12 0.41 to 3.19	SAFIGL_PO_90MG_QD	0.93 0.13 to 9.87	0.92 0.12 to 9.38	0.90 0.11 to 10.15	0.87 0.06 to 15.63	0.76 0.08 to 10.07	0.73 0.05 to 11.45	0.65 0.03 to 13.67	0.61 0.05 to 8.34	0.54 0.04 to 8.66	0.36 0.03 to 5.60
SEMA_SC_1p0MG_QW	4.37 2.08 to 9.87	269 19.94 to 8003	60.49 5.73 to 2221	50.75 4.04 to 2143	48.05 2.11 to 2262	40.71 3.60 to 1794	20.71 0.86 to 582	20.57 7.96 to 66.89	10.52 1.78 to 80.64	7.73 0.12 to 712	7.22 0.09 to 776	7.07 0.08 to 867	6.35 0.17 to 165	6.13 0.09 to 669	5.95 0.08 to 742	3.48 0.58 to 30.29	3.37 0.15 to 94.13	3.02 0.51 to 26.54	3.01 0.13 to 61.92	2.90 0.18 to 58.88	2.87 0.50 to 16.22	2.84 0.38 to 25.85	2.48 1.18 to 5.74	2.02 0.17 to 22.43	1.99 0.58 to 6.99	1.89 0.18 to 14.78	1.79 0.39 to 8.77	1.76 0.08 to 42.76	1.64 0.33 to 7.65	1.61 1.04 to 2.55	1.62 0.32 to 9.26	1.58 0.30 to 7.83	1.33 0.10 to 16.06	1.31 0.16 to 9.12	1.20 0.12 to 8.98	1.07 0.10 to 7.61	SEMA_SC_1p0MG_QW	0.97 0.38 to 2.39	0.96 0.32 to 2.99	0.91 0.15 to 5.67	0.82 0.16 to 3.65	0.77 0.10 to 4.93	0.67 0.06 to 7.39	0.65 0.10 to 3.29	0.58 0.08 to 3.64	0.39 0.05 to 2.31
LIRA_SC_1p8MG_QD	4.48 2.03 to 10.97	278 20.80 to 8023	63.65 5.22 to 2438	50.38 4.76 to 2194	49.65 2.24 to 2204	42.87 3.28 to 1875	21.75 0.86 to 616	21.49 6.64 to 85.23	10.82 1.83 to 83.75	7.77 0.13 to 760	7.45 0.09 to 821	7.25 0.09 to 907	6.54 0.18 to 178	6.28 0.09 to 715	6.18 0.08 to 772	3.56 0.69 to 26.99	3.53 0.15 to 98.54	3.17 0.44 to 30.20	3.08 0.13 to 67.10	3.01 0.19 to 60.51	2.95 0.51 to 18.21	2.98 0.40 to 27.11	2.55 1.13 to 6.42	2.08 0.18 to 23.73	2.05 0.58 to 7.85	1.95 0.19 to 17.10	1.87 0.35 to 10.18	1.78 0.08 to 44.03	1.69 0.32 to 8.91	1.66 0.64 to 4.56	1.67 0.38 to 8.57	1.65 0.31 to 8.45	1.39 0.10 to 16.56	1.34 0.16 to 9.42	1.23 0.12 to 10.16	1.09 0.11 to 8.35	1.03 0.42 to 2.64	LIRA_SC_1p8MG_QD	0.97 0.47 to 2.27	0.94 0.14 to 6.98	0.86 0.17 to 3.81	0.81 0.10 to 5.34	0.69 0.06 to 7.14	0.67 0.10 to 3.51	0.59 0.08 to 3.70	0.41 0.05 to 2.52
SEMA_PO_14MG_QD	4.59 1.67 to 12.22	284 19.71 to 8944	65.37 4.81 to 2767	51.77 4.13 to 2145	49.69 2.05 to 2401	44.46 2.98 to 1997	21.97 0.85 to 650	21.79 5.49 to 93.05	10.65 1.88 to 85.43	7.89 0.13 to 764	7.52 0.09 to 870	7.13 0.08 to 936	6.54 0.16 to 179	6.44 0.08 to 757	6.32 0.08 to 829	3.56 0.80 to 23.77	3.60 0.14 to 96.59	3.26 0.38 to 32.13	3.08 0.13 to 71.36	3.00 0.18 to 59.87	3.00 0.48 to 18.78	2.97 0.38 to 27.54	2.63 0.88 to 7.91	2.13 0.17 to 23.40	2.08 0.50 to 8.08	1.97 0.18 to 17.73	1.89 0.29 to 10.91	1.83 0.07 to 47.01	1.72 0.28 to 9.60	1.68 0.53 to 5.27	1.69 0.45 to 7.35	1.68 0.28 to 9.07	1.41 0.10 to 17.49	1.36 0.15 to 10.03	1.25 0.11 to 10.31	1.11 0.10 to 8.85	1.05 0.33 to 3.13	1.03 0.44 to 2.12	SEMA_PO_14MG_QD	0.96 0.12 to 7.31	0.87 0.15 to 4.12	0.82 0.10 to 5.47	0.71 0.05 to 8.03	0.67 0.09 to 3.76	0.61 0.08 to 4.10	0.41 0.05 to 2.68
ICOSEMA_SC_TIT_QW	4.76 0.71 to 32.30	297 13.13 to 12729	67.76 3.63 to 3462	58.34 2.50 to 3300	51.09 1.51 to 3029	46.32 2.17 to 2607	22.59 0.59 to 1016	22.94 2.89 to 191	11.54 0.97 to 170	8.78 0.09 to 1117	7.74 0.07 to 1182	7.80 0.07 to 1235	6.62 0.13 to 259	6.84 0.07 to 977	6.30 0.07 to 1049	3.83 0.31 to 61.08	3.72 0.10 to 173	3.38 0.26 to 49.60	3.26 0.09 to 114	3.25 0.13 to 95.89	3.16 0.28 to 35.75	3.10 0.24 to 51.06	2.75 0.41 to 18.94	2.22 0.11 to 44.58	2.19 0.25 to 17.93	2.10 0.11 to 30.97	2.00 0.19 to 21.01	1.85 0.05 to 74.11	1.78 0.16 to 18.92	1.77 0.26 to 11.52	1.76 0.17 to 20.77	1.74 0.16 to 17.64	1.44 0.06 to 30.41	1.39 0.09 to 18.78	1.32 0.07 to 18.31	1.15 0.06 to 15.83	1.09 0.18 to 6.54	1.06 0.14 to 7.19	1.04 0.14 to 8.34	ICOSEMA_SC_TIT_QW	0.89 0.08 to 8.42	0.85 0.06 to 10.83	0.73 0.04 to 13.15	0.70 0.05 to 7.71	0.63 0.05 to 7.56	0.42 0.03 to 5.01
EFPE_SC_6MG_QW	5.31 1.56 to 21.98	328 21.32 to 10919	77.45 4.72 to 3495	63.88 3.70 to 2711	59.32 2.26 to 3148	52.49 2.87 to 2642	26.09 0.93 to 898	25.72 4.57 to 170	12.86 1.63 to 139	9.39 0.14 to 1058	8.97 0.10 to 1053	8.62 0.10 to 1027	7.73 0.18 to 239	7.83 0.09 to 1057	7.27 0.09 to 1050	4.25 0.53 to 48.82	4.13 0.16 to 145	3.76 0.37 to 50.50	3.71 0.12 to 91.84	3.62 0.18 to 85.75	3.49 1.04 to 13.70	3.52 0.37 to 44.79	3.05 0.64 to 16.94	2.45 0.17 to 38.17	2.44 0.51 to 13.15	2.35 0.18 to 24.62	2.18 0.29 to 18.27	2.17 0.08 to 66.08	1.97 0.27 to 16.23	1.96 0.44 to 10.21	1.97 0.27 to 17.47	1.94 0.67 to 5.86	1.63 0.10 to 24.27	1.55 0.16 to 14.42	1.48 0.11 to 15.50	1.32 0.10 to 13.13	1.22 0.27 to 6.21	1.17 0.26 to 5.92	1.15 0.24 to 6.53	1.12 0.12 to 11.96	EFPE_SC_6MG_QW	0.96 0.10 to 8.34	0.85 0.05 to 10.84	0.78 0.10 to 5.71	0.70 0.08 to 5.96	0.48 0.05 to 4.03
SEMA_SC_16MG_QW	5.65 1.05 to 39.00	356 19.30 to 14331	84.09 3.77 to 4564	68.94 3.17 to 3814	64.43 2.00 to 3900	58.73 2.43 to 3374	26.63 0.77 to 1140	27.56 3.36 to 256	13.92 1.34 to 206	10.21 0.12 to 1258	9.45 0.10 to 1320	9.30 0.09 to 1465	8.04 0.16 to 317	8.19 0.08 to 1243	8.08 0.07 to 1287	4.60 0.39 to 69.34	4.35 0.13 to 190	4.14 0.29 to 71.12	3.85 0.11 to 128	3.85 0.16 to 113	3.82 0.38 to 41.30	3.77 0.29 to 61.60	3.20 0.48 to 25.74	2.65 0.14 to 51.61	2.59 0.37 to 21.58	2.46 0.15 to 37.21	2.39 0.23 to 26.81	2.28 0.06 to 89.02	2.15 0.21 to 24.48	2.10 0.31 to 16.13	2.11 0.21 to 25.97	2.09 0.22 to 20.52	1.72 0.09 to 34.98	1.64 0.40 to 7.16	1.53 0.10 to 22.25	1.37 0.09 to 18.41	1.29 0.20 to 9.76	1.23 0.19 to 10.05	1.22 0.18 to 10.15	1.18 0.09 to 16.58	1.04 0.12 to 10.41	SEMA_SC_16MG_QW	0.87 0.05 to 15.80	0.83 0.07 to 9.21	0.76 0.06 to 9.27	0.51 0.15 to 1.55
DANU_PO_80MG_BID	6.50 0.69 to 70.61	423 14.27 to 23922	97.38 3.41 to 7049	80.84 2.55 to 5315	72.94 1.57 to 5252	66.29 2.02 to 4980	31.93 0.69 to 1660	31.81 2.53 to 480	15.94 0.95 to 335	11.54 0.12 to 2091	10.87 0.09 to 1892	10.80 0.08 to 2096	9.43 0.14 to 479	9.45 0.07 to 1757	9.33 0.07 to 1689	5.34 0.32 to 121	5.24 0.12 to 273	4.69 0.24 to 105	4.52 0.11 to 185	4.18 0.43 to 74.95	4.33 0.29 to 75.59	4.40 0.24 to 107	3.70 0.34 to 48.51	3.03 0.12 to 85.34	2.99 0.26 to 39.65	2.82 0.13 to 59.55	2.73 0.17 to 47.11	2.56 0.06 to 148	2.43 0.16 to 42.55	2.40 0.21 to 29.59	2.51 0.16 to 43.26	2.31 0.17 to 40.28	1.98 0.25 to 17.45	1.92 0.10 to 36.40	1.77 0.08 to 36.29	1.55 0.07 to 31.76	1.48 0.14 to 18.03	1.45 0.14 to 18.12	1.40 0.12 to 19.42	1.38 0.08 to 27.90	1.18 0.09 to 18.42	1.15 0.06 to 21.45	DANU_PO_80MG_BID	0.94 0.06 to 16.97	0.84 0.05 to 16.72	0.57 0.03 to 10.27
LIXI_SC_20UG_QD	6.61 1.62 to 39.34	440 22.59 to 17125	101 5.52 to 4980	80.91 4.19 to 4641	77.03 2.65 to 4239	69.52 3.51 to 3721	32.90 1.10 to 1248	32.66 5.45 to 275	16.82 1.75 to 210	12.00 0.19 to 1385	11.06 0.12 to 1536	11.10 0.12 to 1579	9.84 0.22 to 358	9.79 0.11 to 1419	9.21 0.10 to 1463	5.63 0.57 to 74.03	5.28 0.18 to 211	4.95 0.43 to 72.03	4.79 0.17 to 127	4.69 0.22 to 127	4.57 0.55 to 43.22	4.61 0.41 to 66.11	3.89 0.70 to 26.58	3.25 0.19 to 53.12	3.13 0.55 to 22.83	2.95 0.22 to 39.70	2.86 0.34 to 28.86	2.80 0.09 to 87.29	2.55 0.30 to 25.63	2.49 0.49 to 16.64	2.62 0.30 to 27.19	2.49 0.33 to 21.89	2.10 0.12 to 38.32	1.98 0.18 to 22.07	1.86 0.14 to 22.91	1.65 0.12 to 19.93	1.55 0.30 to 10.03	1.50 0.28 to 9.97	1.48 0.27 to 10.61	1.43 0.13 to 18.33	1.28 0.18 to 10.27	1.21 0.11 to 13.53	1.06 0.06 to 16.75	LIXI_SC_20UG_QD	0.91 0.41 to 2.08	0.60 0.06 to 6.46
EXEN_SC_10UG_BID	7.47 1.45 to 49.00	490 22.77 to 19388	113 5.60 to 5695	90.37 4.09 to 5234	84.33 2.63 to 5113	76.60 3.38 to 4434	35.99 1.13 to 1512	35.84 5.16 to 316	18.57 1.75 to 249	13.24 0.19 to 1675	12.36 0.12 to 1765	12.30 0.11 to 1799	11.03 0.22 to 405	10.79 0.12 to 1633	10.42 0.11 to 1608	6.35 0.55 to 87.85	5.80 0.20 to 266	5.51 0.42 to 86.35	5.21 0.17 to 158	5.26 0.21 to 150	5.02 0.55 to 50.93	5.15 0.39 to 78.47	4.37 0.65 to 33.27	3.59 0.20 to 64.74	3.47 0.51 to 26.58	3.24 0.21 to 44.11	3.18 0.32 to 34.57	3.09 0.09 to 99.60	2.83 0.28 to 31.15	2.79 0.45 to 20.34	2.90 0.28 to 31.79	2.76 0.31 to 25.99	2.34 0.12 to 45.35	2.23 0.18 to 28.80	2.03 0.14 to 26.40	1.85 0.12 to 23.56	1.73 0.27 to 12.26	1.70 0.27 to 12.07	1.65 0.24 to 12.48	1.58 0.13 to 21.54	1.43 0.17 to 12.44	1.32 0.11 to 16.21	1.19 0.06 to 21.32	1.10 0.48 to 2.43	EXEN_SC_10UG_BID	0.67 0.06 to 7.88
SEMA_SC_8MG_QW	11.13 2.33 to 73.87	718 40.47 to 27961	167 8.03 to 9083	137 6.61 to 7577	128 4.21 to 7273	115 5.44 to 6290	54.59 1.61 to 2296	54.06 7.56 to 468	27.64 2.63 to 417	20.70 0.25 to 2520	19.13 0.18 to 2627	18.34 0.18 to 3063	16.47 0.33 to 607	16.56 0.17 to 2418	16.13 0.17 to 2614	9.07 0.84 to 137	8.85 0.26 to 370	8.21 0.64 to 130	7.85 0.24 to 241	7.75 0.34 to 236	7.60 0.75 to 84.01	7.56 0.61 to 123	6.51 0.99 to 51.23	5.19 0.29 to 103	5.24 0.78 to 41.05	4.85 0.31 to 74.75	4.69 0.51 to 49.49	4.58 0.13 to 183	4.24 0.44 to 47.35	4.17 0.66 to 30.42	4.24 0.45 to 49.30	4.18 0.47 to 40.82	3.49 0.19 to 69.72	3.25 0.93 to 13.89	3.05 0.20 to 42.11	2.75 0.18 to 36.30	2.59 0.43 to 18.96	2.46 0.40 to 18.92	2.46 0.37 to 20.70	2.38 0.20 to 32.30	2.10 0.25 to 19.86	1.97 0.65 to 6.67	1.75 0.10 to 30.59	1.65 0.15 to 17.84	1.49 0.13 to 17.13	SEMA_SC_8MG_QW

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.183 (95% CrI 0.034 to 0.634), log scale
Residual deviance: 99.1 for 107 data points
DIC: 162.8 (pD 63.7)
Largest R-hat: 1.003
Smallest ESS: bulk 2,033, tail 1,967
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-3.23, 1.79^2) on tau^2 (Withdrawals/drop-outs, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Sex (percent female) effect modifier, prognostic factor; 39 of 41	Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 37 of 41
NCT00754988 S000027	44.91	8.82
PIONEER 4 S000133	48	13.4
COMBINE 2 S000155	41.87	27.65
STEP HFpEF DM S000161	44.33	12.31
NCT01476475 S000191	48.92	0.62
OUTSTAND-1 S000213	33.09	100
NCT01001104 S000232	26.19	100 region: all sites in Asia
PIONEER 10 S000234	25.74	100
AWARD-7 S000237	47.69	3.01
NCT01584232 S000246	28.51	100
SUSTAIN™ 3 S000329	44.53	not reported
NCT01029886 S000352	45.49	12
SUSTAIN 11 S000363	48.86	19.55
NCT00976937 S000415	59.9 100 minus male share	0.6
SUSTAIN 9 S000483	41.72	23.51
LIRA-PRIME S000508	47.55	14.6
NCT06589765 S000558	35.68	100 region: all sites in Asia
GetGoal-Duo1 S000792	50.22	19.5
NCT01558271 S000837	19	98.98
SUSTAIN™1 S000878	45.62	21.4
LIRA-Ramadan™ S000963	50.75	45.14
NCT02200991 S001003	37.5 100 minus male share	100 region: all sites in Asia
LIRA-SWITCH™ S001119	40.5	not reported
NCT05514535 S001161	44.19	9.61
SUSTAIN S001311	42.5	85.03
NCT04552470 S001336	13.51	100
GETGOAL-X S001439	46.32	1.1
SUSTAIN™ S001498	28.47	100 region: all sites in Asia
NCT05486065 S001555	48.69	1.49
SUSTAIN™ 5 S001872	43.83	16.67
SUSTAIN™ 2 S001876	not reported	25.1
LIRAFLAME S001895	15.7	not reported
AMPLITUDE-M S002081	46.06	not reported
Lixilan-L-CN S002110	41.81 100 minus male share	100 region: all sites in Asia
NCT03311724 S002256	40.54	3.6
S002946 S002946	18.7 100 minus male share	100 region: all sites in Asia
S003070 S003070	16.67	100 region: all sites in Asia
S003071 S003071	34.35	100 region: all sites in Asia
S003079 S003079	not reported	100 region: all sites in Asia
S003108 S003108	50 100 minus male share	100 region: all sites in Asia
S003426 S003426	62.05	100 region: all sites in Asia

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Sex: design means range from 13.5 (DANU_PO_120MG_BID vs DANU_PO_40MG_BID vs DANU_PO_80MG_BID vs PLACEBO) to 62.1 (SEMA_SC_0p5MG_QW vs TIRZ_SC_5MG_QW) percent female; threshold 15
FlagBaseline, Asian ancestry or region: design means range from 1.1 (EXEN_SC_10UG_BID vs LIXI_SC_20UG_QD) to 100.0 (DANU_PO_120MG_BID vs DANU_PO_40MG_BID vs DANU_PO_80MG_BID vs PLACEBO) percent Asian; threshold 30
FlagEligibility, hba1c entry range: a design requires hba1c 9 or more while another admits only 8 or less
NoteOutcome assessment, time point: selected time points span 2 to 156 weeks
NoteOutcome assessment, analysis set: mixed: completers 1, modified_itt 2, other 1, randomized 3, safety 34
NoteOutcome assessment, definition: mixed: ADA severe hypoglycemia 1, gastrointestinal adverse events leading to treatment discontinuation 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia requiring medical assistance 1, hypoglycemia requiring third party assistance 1, level 3 severe hypoglycemia 1, mild hypoglycemia, undefined 1, not stated 24, severe hypoglycemia 1, severe hypoglycemia by ADA classification 1, severe hypoglycemia needing assistance of another person 1, Severe symptomatic hypoglycemia 1, severe symptomatic hypoglycemia needing assistance 1, severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery 1, severe, assistance of another person required 1, severe, needing assistance of another person 1, symptomatic hypoglycemia confirmed below 3.3 mmol/L 1, Zero implied by no hypoglycemia of any kind 1
NoteOutcome assessment, proportion method: mixed: not stated 39, observed 2
NoteOutcome assessment, intercurrent events (discontinuation): mixed: hypothetical 1, not stated 39, while_on_treatment 1
NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 2, not stated 38, treatment_policy 1
NoteRisk of bias, blinding: mixed: double_blind 20, open_label 18, single_blind 3
NoteRisk of bias, funding: mixed: industry 34, mixed 1, non_industry 4, not_reported 2
NoteData handling, input conversions: arms_combined 1, count_from_percent 2, printed_denominator 3

Comparability items per trial
Trial	time weeks	analysis set	instrument	definition	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT00754988	156	safety	not stated	hypoglycemia adverse event, definition not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
PIONEER 4	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
COMBINE 2	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent
STEP HFpEF DM	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 or older; heart failure with LVEF 45% or more; BMI 30 or more; type 2 diabetes with HbA1c 10% or less
NCT01476475	24	safety	not stated	Severe symptomatic hypoglycemia	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
OUTSTAND-1	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
NCT01001104	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	52	safety	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
AWARD-7	52	safety	not stated	severe hypoglycemia needing assistance of another person	not stated	not stated	hypothetical	hypothetical	single_blind	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT01584232	26	safety	not stated	severe, needing assistance of another person	not stated	not stated	not stated	hypothetical	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
SUSTAIN™ 3	56	safety	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2013	age 18 or older; T2D on stable 1 to 2 oral drugs; HbA1c 7.0 to 10.5 percent; eGFR 60 or more
NCT01029886	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
SUSTAIN 11	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	adults; HbA1c above 7.5 to 10.0 percent on insulin glargine plus metformin
NCT00976937	24	safety	not stated	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day
SUSTAIN 9	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU
LIRA-PRIME	105	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults; HbA1c 7.5 to 9.0 percent; stable metformin monotherapy
NCT06589765	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
GetGoal-Duo1	24	safety	not stated	symptomatic hypoglycemia confirmed below 3.3 mmol/L	not stated	observed	not stated	not stated	double_blind	industry	2009	T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT01558271	52	safety	not stated	severe, assistance of another person required	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
SUSTAIN™1	35	safety	not stated	severe hypoglycemia by ADA classification	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more
LIRA-Ramadan™	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan
NCT02200991	4.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
LIRA-SWITCH™	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more
NCT05514535	45	safety	not stated	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
SUSTAIN	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
NCT04552470	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	Japanese adults 20 to 70, diet and exercise only, HbA1c 7 to 10.5 percent, BMI 22.5 to 45.4
GETGOAL-X	24	safety	not stated	severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	open_label	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
SUSTAIN™	62	safety	not stated	gastrointestinal adverse events leading to treatment discontinuation	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
NCT05486065	49	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
SUSTAIN™ 5	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
SUSTAIN™ 2	56	safety	not stated	ADA severe hypoglycemia	not stated	not stated	not stated	not stated	double_blind	industry	2013	type 2 diabetes on metformin and or thiazolidinedione; HbA1c 7.0 to 10.5 percent
LIRAFLAME	26	other	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2017	T2D; age above 50; HbA1c 48 mmol/mol or more; eGFR 30 or more
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
Lixilan-L-CN	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
NCT03311724	12	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
S002946	26	randomized	not stated	Zero implied by no hypoglycemia of any kind	not stated	not stated	not stated	not stated	open_label	not_reported	2020	age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months
S003070	2	completers	not stated	severe hypoglycemia	not stated	not stated	not stated	not stated	open_label	not_reported		newly diagnosed hospitalized T2D; age 25 to 70; HbA1c 9 to 14 percent; BMI 25 to 35
S003071	24	randomized	not stated	hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to under 80; HbA1c 6.9 to 9.4 percent NGSP; BMI 35 or less; on sulfonylurea
S003079	5	safety	not stated	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months
S003108	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry	2012	T2D with coronary artery disease; no severe heart failure; creatinine up to 150 umol/L
S003426	24	safety	not stated	mild hypoglycemia, undefined	not stated	not stated	not stated	not stated	open_label	non_industry		adults with type 2 diabetes; HbA1c 6.5 to 8.0 percent; BMI 30 to 35; stable metformin and empagliflozin

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT00754988	A2	TASP_SC_10MG_QW	156	arm, events	34 / 190		R0022521:Table 2
NCT00754988	A3	TASP_SC_20MG_QW	156	arm, events	39 / 198		R0022521:Table 2
NCT00754988	A4	SITAGLIPTIN	156	arm, events	3 / 185		R0022521:Table 2
PIONEER 4	A1	SEMA_PO_14MG_QD	52	arm, events	22 / 285		R0015836:Table 3
PIONEER 4	A2	LIRA_SC_1p8MG_QD	52	arm, events	17 / 284		R0015836:Table 3
PIONEER 4	A3	PLACEBO	52	arm, events	3 / 142		R0015836:Table 3
COMBINE 2	A1	ICOSEMA_SC_TIT_QW	57	arm, events	3 / 342		R0005851:Results
COMBINE 2	A2	SEMA_SC_1p0MG_QW	57	arm, events	2 / 341		R0005851:Results
STEP HFpEF DM	A1	SEMA_SC_2p4MG_QW	52	arm, events	20 / 310		R0020223:Table 3
STEP HFpEF DM	A2	PLACEBO	52	arm, events	9 / 306		R0020223:Table 3
NCT01476475	A1	IGLARLIXI2_SC_TIT_QD	24	arm, events	2 / 161		R0021236:p5
NCT01476475	A2	INS_GLARGINE	24	arm, events	0 / 162		R0021236:p5
OUTSTAND-1	A1	SAFIGL_PO_30MG_QD	32	arm, events	0 / 70		R0011607:Table 3
OUTSTAND-1	A2	SAFIGL_PO_60MG_QD	32	arm, events	2 / 70		R0011607:Table 3
OUTSTAND-1	A3	SAFIGL_PO_90MG_QD	32	arm, events	3 / 72		R0011607:Table 3
OUTSTAND-1	A4	PLACEBO	32	arm, events	0 / 72		R0011607:Table 3
NCT01001104	A1	PLACEBO	16	arm, events	0 / 37		R0015000:Results
NCT01001104	A2	DULA_SC_0p25MG_QW	16	arm, events	0 / 36		R0015000:Results
NCT01001104	A3	DULA_SC_0p5MG_QW	16	arm, events	0 / 37		R0015000:Results
NCT01001104	A4	DULA_SC_0p75MG_QW	16	arm, events	0 / 35		R0015000:Results
PIONEER 10	A1	SEMA_PO_3MG_QD	52	arm, events	2 / 131		R0018421:Table 2
PIONEER 10	A2	SEMA_PO_7MG_QD	52	arm, events	4 / 132		R0018421:Table 2
PIONEER 10	A3	SEMA_PO_14MG_QD	52	arm, events	5 / 130		R0018421:Table 2
PIONEER 10	A4	DULA_SC_0p75MG_QW	52	arm, events	1 / 65		R0018421:Table 2
AWARD-7	A1	INS_GLARGINE	52	arm, events	0 / 194		R0017387:Results
AWARD-7	A2	DULA_SC_0p75MG_QW	52	arm, events	4 / 190		R0017387:Results
AWARD-7	A3	DULA_SC_1p5MG_QW	52	arm, events	13 / 193		R0017387:Results
NCT01584232	A1	DULA_SC_0p75MG_QW	26	arm, events	1 / 181		R0016159:Results
NCT01584232	A2	INS_GLARGINE	26	arm, events	0 / 180		R0016159:Results
SUSTAIN™ 3	A1	SEMA_SC_1p0MG_QW	56	arm, events	24 / 406	count_from_percent	R0013158:Supplement Table S4
SUSTAIN™ 3	A2	EXENER_SC_2MG_QW	56	arm, events	12 / 407	count_from_percent	R0013158:Supplement Table S4
NCT01029886	A1	EXENER_SC_2MG_QW	26	arm, events	6 / 461		R0011287:Table 3
NCT01029886	A2	LIRA_SC_1p8MG_QD	26	arm, events	18 / 451		R0011287:Table 3
SUSTAIN 11	A1	SEMA_SC_1p0MG_QW	52	arm, events	15 / 874		R0022346:Table 3
SUSTAIN 11	A2	INS_ASPART	52	arm, events	0 / 874		R0022346:Table 3
NCT00976937	A1	LIXI_SC_20UG_QD	24	arm, events	1 / 158		R0012687:Table 2
NCT00976937	A2	SITAGLIPTIN	24	arm, events	0 / 161		R0012687:Table 2
SUSTAIN 9	A1	SEMA_SC_1p0MG_QW	36	arm, events	10 / 151		R0021710:Table 2
SUSTAIN 9	A2	PLACEBO	36	arm, events	0 / 151		R0021710:Table 2
LIRA-PRIME	A1	LIRA_SC_FLEX_0p6-1p2-1p8_QD	105	arm, events	54 / 996		R0022482:Supplement Table S7
LIRA-PRIME	A2	OTHER_ACTIVE_investigator_choice_oral_drug	105	arm, events	9 / 995		R0022482:Supplement Table S7
NCT06589765	A1	SAFIGL_PO_30MG_QD	52	arm, events	6 / 202		R0029347:Table 3
NCT06589765	A2	SAFIGL_PO_60MG_QD	52	arm, events	7 / 203		R0029347:Table 3
NCT06589765	A3	SAFIGL_PO_90MG_QD	52	arm, events	7 / 203		R0029347:Table 3
NCT06589765	A4	DAPAGLIFLOZIN	52	arm, events	0 / 202		R0029347:Table 3
GetGoal-Duo1	A1	PLACEBO	24	arm, events	0 / 223		R0026107:Results
GetGoal-Duo1	A2	LIXI_SC_20UG_QD	24	arm, events	10 / 223		R0026107:Results
NCT01558271	A1	DULA_SC_0p75MG_QW	52	arm, events	1 / 281		R0011754:Results
NCT01558271	A2	LIRA_SC_0p9MG_QD	52	arm, events	4 / 141		R0011754:Results
SUSTAIN™1	A1	SEMA_SC_0p5MG_QW	35	arm, events	5 / 129		R0021710:Table 2
SUSTAIN™1	A2	SEMA_SC_1p0MG_QW	35	arm, events	4 / 130		R0021710:Table 2
SUSTAIN™1	A3	PLACEBO	35	arm, events	1 / 129		R0021710:Table 2
LIRA-Ramadan™	A1	LIRA_SC_1p8MG_QD	30	arm, events	11 / 172		R0025756:Supplement Table S2
LIRA-Ramadan™	A2	OTHER_ACTIVE_sulfonylurea	30	arm, events	0 / 171		R0025756:Supplement Table S2
NCT02200991	A1	LIXI_SC_20UG_QD	4.43	arm, events	2 / 69		R0024589:Results
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	0 / 67		R0024589:Results
LIRA-SWITCH™	A1	LIRA_SC_1p8MG_QD	27	arm, events	9 / 203		R0025720:Results
LIRA-SWITCH™	A2	SITAGLIPTIN	27	arm, events	0 / 204		R0025720:Results
NCT05514535	A1	SEMA_SC_2p0MG_QW	45	arm, events	4 / 288		R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	0 / 285		R0015842:Table 2
SUSTAIN	A1	SEMA_SC_0p5MG_QW	30	arm, events	10 / 288		R0014802:Table 3
SUSTAIN	A2	SEMA_SC_1p0MG_QW	30	arm, events	21 / 290		R0014802:Table 3
SUSTAIN	A3	SITAGLIPTIN	30	arm, events	1 / 290		R0014802:Table 3
NCT04552470	A1	PLACEBO	12	arm, events	0 / 9		R0004540:Results
NCT04552470	A2	DANU_PO_40MG_BID	12	arm, events	2 / 10		R0004540:Results
NCT04552470	A3	DANU_PO_80MG_BID	12	arm, events	3 / 9		R0004540:Supplement Table S1
NCT04552470	A4	DANU_PO_120MG_BID	12	arm, events	1 / 9		R0004540:Results
GETGOAL-X	A1	LIXI_SC_20UG_QD	24	arm, events	20 / 320		R0022279:Results
GETGOAL-X	A2	EXEN_SC_10UG_BID	24	arm, events	24 / 319		R0022279:Results
SUSTAIN™	A1	SEMA_SC_0p5MG_QW	62	arm, events	7 / 239		R0025024:Figure 1
SUSTAIN™	A2	SEMA_SC_1p0MG_QW	62	arm, events	18 / 241		R0025024:Figure 1
SUSTAIN™	A3	OTHER_ACTIVE_additional_OAD	62	arm, events	0 / 121		R0025024:Figure 1
NCT05486065	A1	SEMA_SC_2p0MG_QW	49	arm, events	4 / 61		R0005510:Supplement Table 5
NCT05486065	A2	SEMA_SC_8MG_QW	49	arm, events	11 / 62		R0005510:Supplement Table 5
NCT05486065	A3	SEMA_SC_16MG_QW	49	arm, events	6 / 62		R0005510:Supplement Table 5
NCT05486065	A4	PLACEBO	49	arm, events	0 / 60		R0005510:Supplement Table 5
SUSTAIN™ 5	A1	SEMA_SC_0p5MG_QW	35	arm, events	3 / 132		R0021710:Table 2
SUSTAIN™ 5	A2	SEMA_SC_1p0MG_QW	35	arm, events	6 / 132		R0021710:Table 2
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	0 / 133		R0021710:Table 2
SUSTAIN™ 2	A1	SEMA_SC_0p5MG_QW	56	arm, events	27 / 409	printed_denominator	R0021710:Table 2
SUSTAIN™ 2	A2	SEMA_SC_1p0MG_QW	56	arm, events	31 / 409	printed_denominator	R0021710:Table 2
SUSTAIN™ 2	A3	SITAGLIPTIN	56	arm, events	3 / 407	printed_denominator	R0021710:Table 2
LIRAFLAME	A1	LIRA_SC_1p8MG_QD	26	arm, events	7 / 51		R0010519:Results
LIRAFLAME	A2	PLACEBO	26	arm, events	0 / 51		R0010519:Results
AMPLITUDE-M	A1	EFPE_SC_2MG_QW	56	arm, events	4 / 100		R0007136:Table 2
AMPLITUDE-M	A2	EFPE_SC_4MG_QW	56	arm, events	7 / 101		R0007136:Table 2
AMPLITUDE-M	A3	EFPE_SC_6MG_QW	56	arm, events	13 / 103		R0007136:Table 2
AMPLITUDE-M	A4	PLACEBO	56	arm, events	2 / 102		R0007136:Table 2
Lixilan-L-CN	A1	IGLARLIXI2_SC_TIT_QD	30	arm, events	2 / 212		R0014540:Results
Lixilan-L-CN	A2	INS_GLARGINE	30	arm, events	0 / 214		R0014540:Results
NCT03311724	A1	PLACEBO	12	arm, events	0 / 26		R0010282:Results
NCT03311724	A2	TIRZ_SC_12MG_QW	12	arm, events	1 / 29		R0010282:Results
NCT03311724	A3+A4	TIRZ_SC_15MG_QW	12	arm, events	1 / 56	arms_combined	R0010282:Results
S002946	A1	SEMA_SC_0p5MG_QW	26	arm, events	1 / 16		R0006360:Supplement Table S2
S002946	A2	DULA_SC_0p75MG_QW	26	arm, events	0 / 16		R0006360:Supplement Table S2
S003070	A1	STANDARD_CARE	2	arm, events	0 / 30		R0024678:p5
S003070	A2	LIRA_SC_1p8MG_QD	2	arm, events	0 / 30		R0024678:p5
S003071	A1	LIRA_SC_0p9MG_QD	24	arm, events	0 / 50		R0023696:Results
S003071	A2	SITAGLIPTIN	24	arm, events	0 / 49		R0023696:Results
S003079	A1	EXEN_SC_10UG_BID	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results
S003108	A1	LIRA_SC_FLEX_0p6-1p2-1p8_QD	24	arm, events	0 / 30		R0025278:Figure 1
S003108	A2	METFORMIN	24	arm, events	0 / 30		R0025278:Figure 1
S003108	A3	LIRA_SC_1p8MG_QD	24	arm, events	0 / 30		R0025278:Figure 1
S003108	A4	LIRAMETF_SC_1p2-1500MG_QD	24	arm, events	0 / 30		R0025278:Figure 1
S003426	A1	SEMA_SC_0p5MG_QW	24	arm, events	3 / 38		R0040396:Table 3
S003426	A2	TIRZ_SC_5MG_QW	24	arm, events	2 / 41		R0040396:Table 3

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab